Bellicum Pharma (BLCM) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cantor Fitzgerald Remains Bullish on Bellicum Pharma (BLCM) Following 4Q
March 14, 2017 7:21 AM EDTCantor Fitzgerald reiterated an Overweight rating and $32.00 price target on Bellicum Pharmaceuticals (NASDAQ: BLCM) following the company's 4Q earnings report and conference call. On the call, management outlined its progress in the BP-004 European registration trial, which will be complemented by a matched unrelated... More
